The difference between Rituximab and Otuzumab

Rituximab and Ocrelizumab are two different drugs, although they both belong to the monoclonal antibody class. Rituximab mainly treats B cell-related diseases, such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, etc. by targeting the CD20 antigen. Otuzumab mainly targets CD20 antigenpatients with previously untreated chronic lymphocytic leukemia.

Rituximab is usually given as an intravenous injection, and treatment regimens typically include weekly or biweekly dosing for several weeks or months. In addition to the above-mentioned indications, rituximab is also used to treat other diseases such as autoimmune thrombocytopenia and rheumatoid arthritis. Otuzumab can be administered by intravenous injection or subcutaneous injection, and the treatment regimen usually includes administration every six months or twice a year. Otuzumab can be combined with bendamustine, followed by otuzumab monotherapy, and is indicated for the treatment of patients with follicular lymphoma who have relapsed or been refractory after rituximab-containing regimens.

Rituximab has been launched in China and has entered the scope of Class B medical insurance. The use of rituximab must be carried out by doctors and medical staff. It is a strictly controlled drug and its purchase and use may be restricted. SpecificationsThe price of each box of 500mg/500mL may be around RMB 8,000, which is relatively expensive. Rituximab has also been launched overseas. The price of the original Indian version of 500mg/500mL per box may be around RMB 3,000 (the price may fluctuate due to exchange rates) . There are also generic rituximab drugs produced by other pharmaceutical companies in India. The price of 500mg/500mL per box may be around 1,500 yuan (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of domestic and foreign original drugs.